HLB PHARMACEUTICAL (047920) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HLB PHARMACEUTICAL (047920) reported revenue of 205.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025205.6 billion KRW1.1 billion KRW4.6 billion KRW[source]
2024137.1 billion KRW1.5 billion KRW2.0 billion KRW[source]
2023136.0 billion KRW-19.5 billion KRW-19.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025166.8 billion KRW41.4 billion KRW125.4 billion KRW[source]
2024157.9 billion KRW41.5 billion KRW116.4 billion KRW[source]
2023141.4 billion KRW53.2 billion KRW88.2 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025569 million KRW-21.3 billion KRW17.9 billion KRW[source]
2024———[source]
2023———[source]

Cash flow figures for the relevant year were not collected.

Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice